JMP Securities Raises Lantheus (NASDAQ:LNTH) Price Target to $130.00

Lantheus (NASDAQ:LNTH) had its target price raised by equities researchers at JMP Securities from $100.00 to $130.00 in a report released on Wednesday, Briefing.com reports. The brokerage presently has an “outperform” rating on the medical equipment provider’s stock. JMP Securities’ price target indicates a potential upside of 22.30% from the company’s previous close.

Several other analysts also recently weighed in on LNTH. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Mizuho raised their target price on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Truist Financial raised their target price on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Finally, B. Riley raised their target price on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $104.17.

Lantheus Trading Up 36.8 %

Shares of NASDAQ LNTH traded up $28.60 during trading on Wednesday, hitting $106.30. 6,483,671 shares of the company traded hands, compared to its average volume of 1,004,379. Lantheus has a 1 year low of $50.20 and a 1 year high of $106.99. The company has a 50-day moving average price of $79.32 and a 200-day moving average price of $66.68. The firm has a market capitalization of $7.37 billion, a P/E ratio of 16.23 and a beta of 0.51. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.11. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The company had revenue of $369.98 million during the quarter, compared to analysts’ expectations of $349.46 million. On average, equities analysts predict that Lantheus will post 6.46 EPS for the current year.

Insider Activity at Lantheus

In related news, insider Daniel Niedzwiecki sold 12,873 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the transaction, the insider now owns 80,244 shares in the company, valued at $6,408,285.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Lantheus news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total transaction of $27,201.57. Following the transaction, the chief accounting officer now directly owns 62,557 shares in the company, valued at approximately $4,990,171.89. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Daniel Niedzwiecki sold 12,873 shares of Lantheus stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the transaction, the insider now owns 80,244 shares in the company, valued at $6,408,285.84. The disclosure for this sale can be found here. Insiders have sold 32,269 shares of company stock worth $2,557,300 over the last quarter. 2.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Clearbridge Investments LLC grew its position in Lantheus by 45.4% during the 4th quarter. Clearbridge Investments LLC now owns 538,782 shares of the medical equipment provider’s stock worth $33,404,000 after purchasing an additional 168,114 shares in the last quarter. South Dakota Investment Council raised its holdings in Lantheus by 139.3% in the 4th quarter. South Dakota Investment Council now owns 27,317 shares of the medical equipment provider’s stock worth $1,694,000 after acquiring an additional 15,900 shares during the period. Silverberg Bernstein Capital Management LLC bought a new position in Lantheus in the 4th quarter worth $1,385,000. Boston Partners increased its holdings in shares of Lantheus by 9.6% during the 4th quarter. Boston Partners now owns 562,125 shares of the medical equipment provider’s stock worth $34,344,000 after purchasing an additional 49,195 shares during the period. Finally, Los Angeles Capital Management LLC increased its holdings in shares of Lantheus by 166.4% during the 1st quarter. Los Angeles Capital Management LLC now owns 42,476 shares of the medical equipment provider’s stock worth $2,644,000 after purchasing an additional 26,530 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.